resTORbio, Inc.
Boston
Massachusetts
United States
About resTORbio, Inc.
resTORbio, Inc., a subsidiary of PureTech Health (LSE: PRTC; www.puretechhealth.com), is developing medicines to treat aging-related diseases and conditions. resTORbio’s lead program is targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio’s lead program is built upon two Phase 2 clinical studies demonstrating promising safety and efficacy results in almost 500 hundred elderly subjects. resTORbio is pursuing a pragmatic clinical development plan addressing areas of key unmet medical need in the aging population.LEADERSHIP:
CEO: Chen Schor
CMO: Joan Mannick
FOLLOW RESTORBIO:
Tweets by resTORbio, Inc.
35 articles with resTORbio, Inc.
-
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
7/30/2020
resTORbio, Inc., a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, provided a corporate update and reported financial results for the second quarter ended June 30, 2020.
-
resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform
7/28/2020
- TrialSpark's integrated tech platform and trial model will enable resTORbio to accelerate their clinical trials of RTB-101 for COVID-19 in community/outpatient settings. [28-July-2020] NEW YORK , July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announ
-
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
7/28/2020
resTORbio resTORbio, Inc. announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled pilot study of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1, as compared to placebo for COVID-19 post-exposure prophylaxis in older adults.
-
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
5/28/2020
resTORbio announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1, as compared to placebo for COVID-19 prophylaxis in nursing home residents.
-
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
5/7/2020
resTORbio, Inc., a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
-
resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
4/30/2020
resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of its employees, stockholders, and other meeting participants, the company has changed the date and format of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”).
-
The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasn’t been announced yet.
-
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
4/29/2020
Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma
-
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
4/3/2020
resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), alone or in combination with sirolimus, in Parkinson’s disease (PD).
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
-
resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
3/12/2020
resTORbio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2019.
-
resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
2/20/2020
resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 9th Annual Leerink Partners Global Healthcare Conference in New York City on Thursday, February 27, 2019 at 10:00 AM ET.
-
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
2/19/2020
-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in preclinical models to inhibit the activity of TORC1 and induce autophagy in neuronal cells --
-
resTORbio to Present at Upcoming Investor Conferences
11/26/2019
resTORbio, Inc. announced that management will present at two upcoming investor conferences
-
Clinical Catch-Up: November 11-15
11/18/2019
It was a busy week for clinical trial announcements. Here’s a look. -
The company halted the development of the drug RTB101 for respiratory disease but will continue to test it in other areas. Look at the reasons behind the halt.
-
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
11/15/2019
resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness (CSRI) in adults age 65 and older,
-
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
11/5/2019
resTORbio, Inc., a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, provided a corporate update and reported financial results for the third quarter ended September 30, 2019.
-
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
10/2/2019
Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults
-
resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections
5/20/2019
RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory confirmation) by 66.4% (p=0.003) as compared to placebo among Phase 2b participants 65 years of age and older with asthma